Epigenetic mechanisms underlying subtype heterogeneity and tumor recurrence in prostate cancer

Prostate cancer is a highly heterogeneous disease. Progression on androgen deprivation therapy (ADT) to castration-resistant (CRPC), or neuroendocrine prostate cancer (NEPC), is associated with poor patient survival. This comment highlights recent evidence on the epigenetic mechanisms underlying the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Goutam, Gupta, Kasmira, Kyprianou, Natasha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895058/
https://www.ncbi.nlm.nih.gov/pubmed/36732329
http://dx.doi.org/10.1038/s41467-023-36253-1
Descripción
Sumario:Prostate cancer is a highly heterogeneous disease. Progression on androgen deprivation therapy (ADT) to castration-resistant (CRPC), or neuroendocrine prostate cancer (NEPC), is associated with poor patient survival. This comment highlights recent evidence on the epigenetic mechanisms underlying the emergence of lineage plasticity and neuroendocrine differentiation in treatment-resistant prostate tumors.

Ejemplares similares